Patents by Inventor Catherine Leblanc

Catherine Leblanc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE
    Publication number: 20220401422
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt form thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of disease.
    Type: Application
    Filed: April 27, 2021
    Publication date: December 22, 2022
    Inventors: Robin Alec FAIRHURST, Christine FRITSCH, Marc GERSPACHER, Jürgen Hans-Hermann HINRICHS, Jean-Baptiste Georges Armand LANGLOIS, Catherine LEBLANC, Tengfei LI, Edwige Liliane Jeanne LORTHIOIS, Christophe MURA, Cristina Montserrat NIETO-OBERHUBER, Milen TODOROV, Andrea VAUPEL, Nicolas WARIN, Rainer WILCKEN
  • Pyrazolyl derivatives useful as anti-cancer agents
    Publication number: 20220363670
    Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 17, 2022
    Inventors: Simona Cotesta, Marc Gerspacher, Catherine Leblanc, Edwige Liliane Jeanne Lorthiois, Bo Liu, Rainer Machauer, Robert Mah, Christophe Mura, Pascal Rigollier, Nadine Schneider, Stefan Stutz, Andrea Vaupel, Nicolas Warin, Rainer Wilcken
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10786492
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: September 29, 2020
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Use of ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 10507201
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 17, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Diana Graus Porta, Carolina Haefliger, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Masato Murakami, Pierre Nimsgern, Michael Palmer, Dale Porter, Sebastien Ripoche, Can Wang, Youzhen Wang, Andreas Weiss, Jing Xiong, Xianglin Zhao
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190231760
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: February 28, 2019
    Publication date: August 1, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNOPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors.
    Publication number: 20190105309
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20190076412
    Abstract: The present invention relates to therapeutic uses of compounds of formula (1) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 13, 2018
    Publication date: March 14, 2019
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Pierre NIMSGERN, Sebastien RIPOCHE, Jing XIONG, Bo HAN, Can WANG, Xianglin ZHAO
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Patent number: 10189813
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 29, 2019
    Assignee: NOVARTIS AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Pharmaceutical combinations
    Patent number: 10130629
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: November 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc, Lv Liao, Robert Mah, Dale Porter, Can Wang, Markus Wartmann, Jing Xiong, Xianglin Zhao
  • USE OF RING-FUSED BICYCLIC PYRIDYL DERIVATIVES AS FGFR4 INHIBITORS
    Publication number: 20180185341
    Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof
    Type: Application
    Filed: October 2, 2015
    Publication date: July 5, 2018
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Diana GRAUS PORTA, Carolina HAEFLIGER, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Masato MURAKAMI, Pierre NIMSGERN, Michael PALMER, Dale PORTER, Sebastien RIPOCHE, Can WANG, Youzhen WANG, Andreas WEISS, Jing XIONG, Xianglin ZHAO
  • PHARMACEUTICAL COMBINATIONS
    Publication number: 20180064709
    Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Jorge Garcia Fortanet, Pascal Furet, Diana Graus Porta, Nafeeza Hafeez, Bo Han, Thomas Knoepfel, Matthew J. LaMarche, Catherine Leblanc
  • Formylated N-heterocyclic derivatives as FGFR4 inhibitors
    Publication number: 20180065951
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: March 23, 2016
    Publication date: March 8, 2018
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knoepfel, Catherine Leblanc, Robert Mah
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 9896449
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: February 20, 2018
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
    Patent number: 9802917
    Abstract: The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: October 31, 2017
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Bo Han, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Franck Mallet, Julie Martz, Can Wang, Jing Xiong, Xianglin Zhao
  • IP receptor agonist heterocyclic compounds
    Patent number: 9604981
    Abstract: The present invention provides heterocyclic derivatives of formula (Ia) which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 28, 2017
    Assignee: Novartis AG
    Inventors: Rebecca Butler, Catherine Leblanc, Stephen Carl McKeown, Steven John Charlton
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Publication number: 20170066766
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Patent number: 9533988
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 3, 2017
    Assignee: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao
  • Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
    Publication number: 20160304489
    Abstract: The present invention relates to particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, to a process of making said particles, to pharmaceutical compositions comprising said particles and to method of treating cancers using said pharmaceutical compositions.
    Type: Application
    Filed: March 18, 2016
    Publication date: October 20, 2016
    Applicant: NOVARTIS AG
    Inventors: Nicole BUSCHMANN, Robin Alec FAIRHURST, Pascal FURET, Bo HAN, Thomas KNÖPFEL, Catherine LEBLANC, Lv LIAO, Robert MAH, Franck MALLET, Julie MARTZ, Can WANG, Jing XIONG, Xianglin ZHAO
  • Bacterial iodoperoxidases from , methods of preparation and uses thereof
    Patent number: 9353354
    Abstract: The present invention concerns iodoperoxidases from Zobellia galactanivorans, isolated nucleic acids encoding same, as well as methods for preparing these enzymes. Moreover, the invention is also directed to the use of such iodoperoxidases in a wide range of industrial, pharmaceutical, medical, cosmetics, and ecological applications, as well as in the food industry.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: May 31, 2016
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Catherine Leblanc, Ludovic Delage, Gurvan Michel, Etienne Rebuffet, Mirjam Czjzek, Philippe Potin
  • Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
    Publication number: 20160102092
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Applicant: Novartis AG
    Inventors: Nicole Buschmann, Robin Alec Fairhurst, Pascal Furet, Thomas Knöpfel, Catherine Leblanc, Lv Liao, Robert Mah, Pierre Nimsgern, Sebastien Ripoche, Jing Xiong, Bo Han, Can Wang, Xianglin Zhao